Member Info for Dosanddonts

Bodes well that the 2 countries they have been selling in for 12month, Eroxon has won awards! Don’t see why this won’t continue into all countries! I would also like to see FUM pick back up where they left off with the other potential products or least a timeline to when that will be! What would the SP have been if they’d had the funds & the R&D had continued??? If the company was sold what are these products worth??

10th April will be the turning point for this Share! With hopefully a clear focus on financials & a detailed plan for the next 12month with profit forecasts, USA timescales to market & ROTW! If not & the BOD give nothing away SP will plummet IMO!

Anybody any idea? I’m only aware of the Boots product if the year!

“Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.”

Well what do you expect? Still very little news flow and people are becoming impatient! FUM have clearly decided not release RNS’s voluntarily and perhaps in JB ‘s case for good reason as he only caused the SP to plummet. But news is coming & when it comes I’m expecting lots of it, not just a yearly update but informative news that will hopefully push the SP upwards!

I suspect FUM will be bought out once they have completed the Donkey work and Eroxon US date is set! People forget FUM have multiple products under R&D and TPR100 was very near commercialisation which again could be a ground breaking product more effective than market leading topical diclofenac with only 20% active ingredient! This focus on one product although essential has also removed SP value IMO! So FUM valuation once these other products are reevaluated plus Eroxon who knows, but how long can FUM ignore its R&D roots??

When results were issued last year there was a video which mentioned future revenue in 2025 when US sales take off with a prediction of £400 million. Work it out everyone it dosnt take Einstein to work out the possible SP and to be honest FUM aren’t great at blowing their own trumpet so this figure will be on the pessimistic side if anything. IMO £1billion valuation is somewhere near for just Eroxon alone, we also have to consider the possible value of the products put on hold to focus on Eroxon.

I’m not expecting any news until end of year financials! Then soon after US launch dates and then a buy-out! Not sure why Barder keeps releasing interviews that tell us nothing ‘US preparations going well’ maybe rephrase that ‘ US preparation going well with possible 2024 launch’ that’s what we want to hear not regurgitated old news & the obvious!

As have many, I’ve been here far too long supporting this share and seen the lows of 7p! I now see a new breed of new investors in the share chat & it’s like ground-hod day 😂! I’ve even been called a de-ramper OMG! 😂😂😂😂😂😂😂😂. I never expected the SP to be struggling at this point and what an opportunity it is for the newbies to get in, wish I’d never invested early doors but it’s well worth it now IMO.

Comek- I don’t de-ramp just like to be factual! Wish I had jumped in & out as wouldn’t be here now!

Comek- NHS prescription value for ED before it was OTC was around £70mill I think I read now at £14mill! Massive reduction as people will go with convenience over cost! for the vast majority anyway. So we may see an uplift but would suspect small percentage

FUM also said they would not be profitable until 2025 which decimated the SP! As for 65/35 split, based on profits and early calculations it’s looks like a 50/50 split but no confirmation of this! As has been said and as I’ve been saying until we see the full financials the SP will swing up and down as too many unknowns!

i don’t see the nhs as a major increase to sales but more a major validation of eroxon being a clinically approved ed product for the masses. don’t see them dishing out ***** pumps sold on amazon? just another route to market for eroxon with nhs approval!

NHS only spent £13mill on ED prescriptions not £100mill I think that includes GP/tests etc. so we are talking about £2mill, but it will be 1st prescribed medication as has fewer side effects, & let’s remember those old foke who can’t take the other medication! WIN WIN & hopefully some free publicity is coming!

This is great for Eroxon, approved my the NHS! This tells people it works as the NHS don’t approve drugs or medical devices that don’t! This will validate the product for many people regardless of reviews IMO!

Toli!!!! If u couldn’t guess

Hope u miss the buy back in & then hopefully you will disappear. Do as you want buying & selling but don’t tell other people what to do you idiot! Bet your a bragger as well just the type of person I hate!

Guessing that £110k was a sell then!

That is a hefty after hours trade at £110k

So now available in Germany, France, Spain & Portugal, & official as it’s on the Eroxon home page with links at the bottom of page! Now seeing reviews on Amazon in Germany from November? Have to eat my words as they are coming Good on their promise's. Guessing this maybe the reason for the rise last week.

SP has now positioned itself for a rise on news again, let’s hope that news comes soon, I’m guessing so as RNS was just an update of already released news apart from the new broker! So gearing itself up for further news releases I’m guessing.